Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Euroz Hartleys Rottnest Island Institutional Conference 2022
13 slides from Firebrick Pharma's conference presentation, Mar 11, 2022
Slide 1: Investor Presentation March 2022
For personal use only INVESTOR PRESENTATION 11 MARCH 2022 EUROZ HARTLEYS ROTTNEST ISLAND INSTITUTIONAL CONFERENCE FIREBRICKPHARMA.COM INVESTOR PRESENTATION MARCH 2022
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this pre
Slide 3: Firebrick IPO Story
FIREBRICK IPO STORY Australian Pharmaceutical Innovator Focused on Infectious Disease For personal use only Breakthrough Product: Nasodine Late-stage Biopharma story Kills1 the viruses that cause colds Nasodine completed Phase 1-3 trials First-in-class nasal spray medicine that Second Phase 3 trial
Slide 4: IPO Performance
IPO PERFORMANCE Listed on ASX as ‘FRE’ on 28 January 2022 For personal use only Extensive media coverage The Firebrick appeal Many early investors were Australian doctors who believe in the product concept Technology story is easy to comprehend: kills viruses in the nose to treat colds Unprecedent p
Slide 5: Nasodine Nasal Spray
NASODINE® NASAL SPRAY For personal use only Australian breakthrough that could be the world’s first approved nasal medicine that actually targets the viral cause of colds Contains povidone-iodine (PVP-I) 0.5% • In a proprietary formulation, safe for use on nasal tissue1 Kills2 all respiratory viruse
Slide 6: Nasodine's Initial Indication: The Common Cold in Adults
Nasodine’s Initial Indication: The COMMON COLD in adults For personal use only VIRUS INFECTION Large addressable market STARTS IN THE NOSE WHERE VIRUSES • 2.5 billion colds annually in US and Europe1 (60 million in AU) MULTIPLY RAPIDLY • High economic cost in lost productivity, doctor visits and med
Slide 7: The Nasodine Breakthrough
THE NASODINE® BREAKTHROUGH For personal use only A cold begins when a virus infects the Nasodine® Nasal Spray disperses through the nasal passages cells lining the nasal passages to target the viruses that cause the infection EXISTING COLD TREATMENTS TARGET NASODINE NASAL SPRAY SYMPTOM RELIEF ONLY T
Slide 8: Common Cold Market Opportunity
COMMON COLD MARKET OPPORTUNITY For personal use only THE PRODUCT THE OPPORTUNITY Dosage for common cold treatment is: 3 sprays per nostril, 4 times daily for 5 days US$40 billion economic Each 25ml bottle contains 30 doses cost of colds in U.S. alone (20 doses needed for each cold) Expected retail p
Slide 9: Manufacturing Ready, Partnership Agreements in Place
MANUFACTURING READY, For personal use only PARTNERSHIP AGREEMENTS IN PLACE AUSTRALIA GLOBAL Firebrick to market all its products directly in Australia Outside Australia, licensed distributors to be used. Agreements already in place in Philippines, New Zealand Management has experience in building sa
Slide 10: Pathway to Approval
PATHWAY TO APPROVAL For personal use only Initial registration dossier submitted to TGA in 2020: • Nasodine met all manufacturing, quality and safety hurdles • But TGA decided that clinical efficacy was not satisfactorily established by the first Phase 3 trial, because the positive result on the sel
Slide 11: Future Opportunities
FUTURE OPPORTUNITIES For personal use only COMMON COLD REDUCING HOSPITAL COVID-19 PRODUCT DEVELOPMENT PREVENTION INFECTION RISK BY PPB & FUTURE PANDEMICS Subject to further clinical Nasodine could be used in Nasodine is effective in vitro Several new products in trials Nasodine could be hospitals to
Slide 12: COVID-19 Phase 2 Clinical Trial
COVID-19 For personal use only PHASE 2 CLINICAL TRIAL Randomised controlled Phase 2 trial in South Africa of Nasodine in COVID-19 patients Subjects: 144 adults who will be confirmed to be actively shedding SARS-CoV-2 STUDY ENDPOINT OTHER OBJECTIVES Goal: Demonstrate that frequent doses of Nasodine s
Slide 13: Outstanding Board with Global Reach and Experience
OUTSTANDING BOARD WITH GLOBAL REACH AND EXPERIENCE For personal use only PETER MOLLOY STEPHEN GOODALL PHYLLIS GARDNER FOUNDER CO-FOUNDER NON-EXECUTIVE EXECUTIVE CHAIRMAN DIRECTOR, COO DIRECTOR BSc, MBA, PhD, FAICD BAppSc, MAppSc, MBA, PhD MD (Harvard) Microbiologist & biochemist who built the Betadi
Firebrick Pharma — Euroz Hartleys Rottnest Island Institutional Conference 2022 on 6ix